vs
Side-by-side financial comparison of Abbott Laboratories (ABT) and Bausch & Lomb Corp (BLCO). Click either name above to swap in a different company.
Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $1.4B, roughly 8.2× Bausch & Lomb Corp). Abbott Laboratories runs the higher net margin — 15.5% vs -4.1%, a 19.6% gap on every dollar of revenue. On growth, Bausch & Lomb Corp posted the faster year-over-year revenue change (9.8% vs 4.4%). Abbott Laboratories produced more free cash flow last quarter ($2.6B vs $60.0M). Over the past eight quarters, Bausch & Lomb Corp's revenue compounded faster (13.1% CAGR vs 7.2%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
ABT vs BLCO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $11.5B | $1.4B |
| Net Profit | $1.8B | $-58.0M |
| Gross Margin | 57.0% | — |
| Operating Margin | 19.6% | 8.0% |
| Net Margin | 15.5% | -4.1% |
| Revenue YoY | 4.4% | 9.8% |
| Net Profit YoY | -80.8% | -1833.3% |
| EPS (diluted) | $1.01 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5B | $1.4B | ||
| Q3 25 | $11.4B | $1.3B | ||
| Q2 25 | $11.1B | $1.3B | ||
| Q1 25 | $10.4B | $1.1B | ||
| Q4 24 | $11.0B | $1.3B | ||
| Q3 24 | $10.6B | $1.2B | ||
| Q2 24 | $10.4B | $1.2B | ||
| Q1 24 | $10.0B | $1.1B |
| Q4 25 | $1.8B | $-58.0M | ||
| Q3 25 | $1.6B | $-28.0M | ||
| Q2 25 | $1.8B | $-62.0M | ||
| Q1 25 | $1.3B | $-212.0M | ||
| Q4 24 | $9.2B | $-3.0M | ||
| Q3 24 | $1.6B | $4.0M | ||
| Q2 24 | $1.3B | $-151.0M | ||
| Q1 24 | $1.2B | $-167.0M |
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
| Q4 25 | 19.6% | 8.0% | ||
| Q3 25 | 18.1% | 7.4% | ||
| Q2 25 | 18.4% | -0.9% | ||
| Q1 25 | 16.3% | -7.3% | ||
| Q4 24 | 17.4% | 6.8% | ||
| Q3 24 | 17.5% | 3.6% | ||
| Q2 24 | 16.1% | 2.1% | ||
| Q1 24 | 13.9% | 0.5% |
| Q4 25 | 15.5% | -4.1% | ||
| Q3 25 | 14.5% | -2.2% | ||
| Q2 25 | 16.0% | -4.9% | ||
| Q1 25 | 12.8% | -18.6% | ||
| Q4 24 | 84.1% | -0.2% | ||
| Q3 24 | 15.5% | 0.3% | ||
| Q2 24 | 12.5% | -12.4% | ||
| Q1 24 | 12.3% | -15.2% |
| Q4 25 | $1.01 | $-0.16 | ||
| Q3 25 | $0.94 | $-0.08 | ||
| Q2 25 | $1.01 | $-0.18 | ||
| Q1 25 | $0.76 | $-0.60 | ||
| Q4 24 | $5.26 | $-0.00 | ||
| Q3 24 | $0.94 | $0.01 | ||
| Q2 24 | $0.74 | $-0.43 | ||
| Q1 24 | $0.70 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9B | $383.0M |
| Total DebtLower is stronger | $12.9B | $5.0B |
| Stockholders' EquityBook value | $52.1B | $6.4B |
| Total Assets | $86.7B | $14.0B |
| Debt / EquityLower = less leverage | 0.25× | 0.78× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.9B | $383.0M | ||
| Q3 25 | $7.7B | $310.0M | ||
| Q2 25 | $7.3B | $266.0M | ||
| Q1 25 | $6.8B | $202.0M | ||
| Q4 24 | $8.0B | $305.0M | ||
| Q3 24 | $7.8B | $329.0M | ||
| Q2 24 | $7.2B | $285.0M | ||
| Q1 24 | $6.7B | $315.0M |
| Q4 25 | $12.9B | $5.0B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.8B | ||
| Q4 24 | $14.1B | $4.8B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $4.6B |
| Q4 25 | $52.1B | $6.4B | ||
| Q3 25 | $51.0B | $6.4B | ||
| Q2 25 | $50.6B | $6.4B | ||
| Q1 25 | $48.8B | $6.4B | ||
| Q4 24 | $47.7B | $6.5B | ||
| Q3 24 | $39.8B | $6.6B | ||
| Q2 24 | $39.3B | $6.5B | ||
| Q1 24 | $38.8B | $6.7B |
| Q4 25 | $86.7B | $14.0B | ||
| Q3 25 | $84.2B | $13.8B | ||
| Q2 25 | $84.0B | $13.8B | ||
| Q1 25 | $81.4B | $13.4B | ||
| Q4 24 | $81.4B | $13.5B | ||
| Q3 24 | $74.4B | $13.5B | ||
| Q2 24 | $73.0B | $13.3B | ||
| Q1 24 | $72.5B | $13.3B |
| Q4 25 | 0.25× | 0.78× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | 0.30× | 0.74× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.71× | ||
| Q1 24 | — | 0.69× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $136.0M |
| Free Cash FlowOCF − Capex | $2.6B | $60.0M |
| FCF MarginFCF / Revenue | 22.9% | 4.3% |
| Capex IntensityCapex / Revenue | 6.0% | 5.4% |
| Cash ConversionOCF / Net Profit | 1.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.4B | $-66.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $136.0M | ||
| Q3 25 | $2.8B | $137.0M | ||
| Q2 25 | $2.0B | $35.0M | ||
| Q1 25 | $1.4B | $-25.0M | ||
| Q4 24 | $2.9B | $22.0M | ||
| Q3 24 | $2.7B | $154.0M | ||
| Q2 24 | $2.0B | $15.0M | ||
| Q1 24 | $1.0B | $41.0M |
| Q4 25 | $2.6B | $60.0M | ||
| Q3 25 | $2.3B | $63.0M | ||
| Q2 25 | $1.5B | $-54.0M | ||
| Q1 25 | $933.0M | $-135.0M | ||
| Q4 24 | $2.1B | $-70.0M | ||
| Q3 24 | $2.1B | $94.0M | ||
| Q2 24 | $1.4B | $-57.0M | ||
| Q1 24 | $627.0M | $-26.0M |
| Q4 25 | 22.9% | 4.3% | ||
| Q3 25 | 20.2% | 4.9% | ||
| Q2 25 | 13.9% | -4.2% | ||
| Q1 25 | 9.0% | -11.9% | ||
| Q4 24 | 19.6% | -5.5% | ||
| Q3 24 | 20.2% | 7.9% | ||
| Q2 24 | 13.8% | -4.7% | ||
| Q1 24 | 6.3% | -2.4% |
| Q4 25 | 6.0% | 5.4% | ||
| Q3 25 | 4.4% | 5.8% | ||
| Q2 25 | 4.5% | 7.0% | ||
| Q1 25 | 4.7% | 9.7% | ||
| Q4 24 | 6.6% | 7.2% | ||
| Q3 24 | 5.2% | 5.0% | ||
| Q2 24 | 5.1% | 5.9% | ||
| Q1 24 | 4.0% | 6.1% |
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | 38.50× | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABT
Segment breakdown not available.
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
